Idioma:

Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study

Chakraborty, Shamik ; Filippi, Christopher G. ; Wong, Tamika ; Ray, Ashley ; Fralin, Sherese ; Tsiouris, A. John ; Praminick, Bidyut ; Demopoulos, Alexis ; McCrea, Heather J. ; Bodhinayake, Imithri ; Ortiz, Rafael ; Langer, David J. ; Boockvar, John A.

Journal of neuro-oncology, 2016-07, Vol.128 (3), p.405-415 [Periódico revisado por pares]

New York: Springer US

Texto completo disponível

Citações Citado por

Enviar para

Título:
Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study
Autor: Chakraborty, Shamik ; Filippi, Christopher G. ; Wong, Tamika ; Ray, Ashley ; Fralin, Sherese ; Tsiouris, A. John ; Praminick, Bidyut ; Demopoulos, Alexis ; McCrea, Heather J. ; Bodhinayake, Imithri ; Ortiz, Rafael ; Langer, David J. ; Boockvar, John A.
Assuntos: Adult ; Aged ; Antineoplastic Agents, Immunological - administration & dosage ; Antineoplastic Agents, Immunological - adverse effects ; Blood-Brain Barrier - drug effects ; Blood-Brain Barrier - metabolism ; Brain Neoplasms - diagnostic imaging ; Brain Neoplasms - drug therapy ; Brain Neoplasms - metabolism ; Cetuximab - administration & dosage ; Cetuximab - adverse effects ; Clinical Study ; Diuretics, Osmotic - therapeutic use ; Drug Therapy, Combination ; Female ; Glioma - diagnostic imaging ; Glioma - drug therapy ; Glioma - metabolism ; Humans ; Infusions, Intra-Arterial ; Male ; Mannitol - therapeutic use ; Maximum Tolerated Dose ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - metabolism ; Neurology ; Oncology ; Treatment Outcome
É parte de: Journal of neuro-oncology, 2016-07, Vol.128 (3), p.405-415
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Objective To establish a maximum tolerated dose of superselective intraarterial cerebral infusion (SIACI) of Cetuximab after osmotic disruption of the blood–brain barrier (BBB) with mannitol, and examine safety of the procedure in patients with recurrent malignant glioma. Methods A total of 15 patients with recurrent malignant glioma were included in the current study. The starting dose of Cetuximab was 100 mg/m 2 and dose escalation was done to 250 mg/m 2 . All patients were observed for 28 days post-infusion for any side effects. Results There was no dose-limiting toxicity from a single dose of SIACI of Cetuximab up to 250 mg/m 2 after osmotic BBB disruption with mannitol. A tolerable rash was seen in 2 patients, anaphylaxis in 1 patient, isolated seizure in 1 patient, and seizure and cerebral edema in 1 patient. Discussion SIACI of mannitol followed by Cetuximab (up to 250 mg/m 2 ) for recurrent malignant glioma is safe and well tolerated. A Phase I/II trial is currently underway to determine the efficacy of SIACI of cetuximab in patients with high-grade glioma.
Editor: New York: Springer US
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 3 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study

Chakraborty, Shamik ; Filippi, Christopher G. ; Wong, Tamika ; Ray, Ashley ; Fralin, Sherese ; Tsiouris, A. John ; Praminick, Bidyut ; Demopoulos, Alexis ; McCrea, Heather J. ; Bodhinayake, Imithri ; Ortiz, Rafael ; Langer, David J. ; Boockvar, John A.

New York: Springer US

Buscando em bases de dados remotas. Favor aguardar.